{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:55:41Z","timestamp":1765356941305,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Patients with progressive thoracic malignancy characterized by large irregular tumors with necrosis and life-threatening symptoms lack effective treatments. We set out to develop a single needle cone puncture method for the Iodine-125 seed (SNCP-<jats:sup>125<\/jats:sup>I) brachytherapy, and aim to report the initial results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>294 patients with advanced thoracic malignancy were treated with local SNCP-<jats:sup>125<\/jats:sup>I brachytherapy between March 2009 and July 2020, followed by thorough evaluation of clinical outcome, overall survival (OS), progression-free survival (PFS) and procedure-related complications after treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate (ORR) among the treated patients was 81.0% (238\/294). Life-threatening symptoms due to tumor oppression, hemoptysis and large irregular tumor with necrosis were successfully alleviated after the SNCP-<jats:sup>125<\/jats:sup>I treatment with a remission rate at 91% to 94%. The median OS and PFS were 13.6 months and 5.8 months, respectively. Procedure-related side effects including pneumothorax (32\/294), blood-stained sputum (8\/294), subcutaneous emphysema (10\/294), puncture site bleeding (16\/294) and chest pain (6\/294) were observed. Patients who were able to follow with chemotherapy or immunotherapy experienced extended OS and PFS, as compared with patients who opted to receive hospice care (16.5 months Vs. 11.2 months). Further pathological and immunological analysis showed that SNCP-<jats:sup>125<\/jats:sup>I induced tumor lymphocytes infiltration and long-term tumor necrosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SNCP-<jats:sup>125<\/jats:sup>I brachytherapy effectively eliminates life-threatening symptoms due to local tumor oppression, hemoptysis and large irregular and necrotic tumors in patients with unresectable chest malignancy and significantly induces local tumor regression. SNCP-<jats:sup>125<\/jats:sup>I brachytherapy combines with chemotherapy significantly prolong OS and PFS compare with SNCP-<jats:sup>125<\/jats:sup>I brachytherapy alone.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.640131","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T06:52:24Z","timestamp":1622443944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["A Retrospective Study on Using a Novel Single Needle Cone Puncture Approach for the Iodine-125 Seed Brachytherapy in Treating Patients With Thoracic Malignancy"],"prefix":"10.3389","volume":"11","author":[{"given":"Fenge","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yixiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenglu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueming","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1186\/s12885-018-5007-0","article-title":"Neo-Adjuvant Treatment of Adenocarcinoma and Squamous Cell Carcinoma of the Cervix Results in Significantly Different Pathological Complete Response Rates","volume":"18","author":"Couvreur","year":"2018","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13048-020-00675-y","article-title":"Poorer Prognosis of Ovarian Squamous Cell Carcinoma Than Serous Carcinoma: A Propensity Score Matching Analysis Based on the SEER Database","volume":"13","author":"Zhang","year":"2020","journal-title":"J Ovarian Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12967-020-02436-3","article-title":"Presence of a 34-Gene Signature is a Favorable Prognostic Marker in Squamous non-Small Cell Lung Carcinoma","volume":"18","author":"Theelen","year":"2020","journal-title":"J Transl Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2218-6751.2015.06.07","article-title":"Treatment of Advanced Squamous Cell Carcinoma of the Lung: A Review","volume":"4","author":"Derman","year":"2015","journal-title":"Transl Lung Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60569-9","article-title":"Cetuximab Plus Chemotherapy in Patients with Advanced non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial","volume":"373","author":"Pirker","year":"2009","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/annonc\/mdu438.51","article-title":"Antitumor Activity of Pembrolizumab (Pembro; MK-3475) and Correlation with Programmed Death Ligand (PD-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced non-Small Cell Lung Carcinoma (NSCLC)","volume":"25","author":"Garon","year":"2014","journal-title":"Ann Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5848","article-title":"Weekly Nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients with Advanced non-Small-Cell Lung Cancer: Final Results of a Phase III Trial","volume":"30","author":"Socinski","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2013.07.014","article-title":"Assessment of Palliative Care for Advanced non-Small-Cell Lung Cancer in France: A Prospective Observational Multicenter Study (GFPC 0804 Study)","volume":"82","author":"Vergnen\u00e8gre","year":"2013","journal-title":"Lung Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1089\/jpm.2016.0064","article-title":"The Impact of Hospice Services in the Care of Patients with Advanced Stage Nonsmall Cell Lung Cancer","volume":"20","author":"Duggan","year":"2017","journal-title":"J Palliat Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-018-4379-7","article-title":"Alliative Care and Psychosocial Care in Metastatic non-Small Cell Lung Cancer: Factors Affecting Utilisation of Services and Impact on Patient Survival","volume":"27","author":"Duggan","year":"2019","journal-title":"Support Care Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e2249","DOI":"10.1097\/MD.0000000000002249","article-title":"125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy","volume":"94","author":"Xiang","year":"2015","journal-title":"Med (Baltimore)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjopt.2017.12.002","article-title":"Characteristics, Management, and Outcome of Patients With Uveal Melanoma Treated by Iodine-125 Radioactive Plaque Therapy in a Single Tertiary Cancer Center in Jordan","volume":"32","author":"Jaradat","year":"2018","journal-title":"Saudi J Ophthalmol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0361-9","article-title":"Efficacy of iodine-125 Seed Implantation in Locoregionally Recurrent and Unresectable Breast Cancer: A Retrospective Study","volume":"25","author":"Yu","year":"2019","journal-title":"Pathol Oncol Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12885-020-07246-w","article-title":"Permanent iodine-125 Brachytherapy for Patients with Progressive or Recurrent High-Grade Gliomas","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000425","article-title":"Permanent Iodine 125 Brachytherapy in Patients with Progressive or Recurrent Glioblastoma Multiforme","volume":"6","author":"Larson","year":"2004","journal-title":"Neuro Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not126","article-title":"Stereotactic iodine-125 Brachytherapy for the Treatment of WHO Grades II and III Gliomas Located in the Central Sulcus Region","volume":"15","author":"Ruge","year":"2013","journal-title":"Neuro Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1533033819825845","DOI":"10.1177\/1533033819825845","article-title":"Permanent iodine-125 Seed Implantation for the Treatment of Nonresectable Retroperitoneal Malignant Tumors","volume":"18","author":"Li","year":"2019","journal-title":"Technol Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i46.5280","article-title":"Preliminary Application of 3D-Printed Coplanar Template for iodine-125 Seed Implantation Therapy in Patients with Advanced Pancreatic Cancer","volume":"24","author":"Huang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S141245","article-title":"The Application of a Three-Dimensional Visualized Seed Planning and Navigation System in 125 I Seed Implantation for Pancreatic Cancer","volume":"11","author":"Hu","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12912","article-title":"Chinese Expert Consensus Workshop Report: Guideline for Permanent iodine-125 Seed Implantation of Primary and Metastatic Lung Tumors","volume":"10","author":"Zhang","year":"2019","journal-title":"Thorac Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/0971-6203.39419","article-title":"Dosimetry and Treatment Planning of Occu-Prosta I-125 Seeds for Intraocular Lesions","volume":"33","author":"Chaudhari","year":"2008","journal-title":"J\u00a0Med Phys"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2017.07.011","article-title":"MRI-Based Treatment Planning and Dose Delivery Verification for Intraocular Melanoma Brachytherapy","volume":"17","author":"Zoberi","year":"2018","journal-title":"Brachytherapy"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.11106","article-title":"Comparison of Pre-Implant Treatment Planning and Post-Implant Dosimetry in I-125 Spinal Metastases Brachytherapy","volume":"19","author":"Chen","year":"2020","journal-title":"Oncol Lett"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrs046","article-title":"A Digital Model Individual Template and CT-guided 125I Seed Implants for Malignant Tumors of the Head and Neck","volume":"53","author":"Huang","year":"2012","journal-title":"J Radiat Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1533033820915710","DOI":"10.1177\/1533033820915710","article-title":"Automatic Planning for Nasopharyngeal Carcinoma Based on Progressive Optimization in RayStation Treatment Planning System","volume":"19","author":"Yang","year":"2020","journal-title":"Technol Cancer Res Treat"},{"key":"B26","unstructured":"Common Terminology Criteria for Adverse Events (Ctcae) Version 4.02009"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.1999.1002","article-title":"Development and Validation of the Cancer Dyspnoea Scale: A Multidimensional, Brief, Self-Rating Scale","volume":"82","author":"Tanaka","year":"2000","journal-title":"Br J Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"97S","DOI":"10.1378\/chest.123.1_suppl.97S","article-title":"Initial Evaluation of the Patient with Lung Cancer: Symptoms, Signs, Laboratory Tests, and Paraneoplastic Syndromes","volume":"123","author":"Beckles","year":"2003","journal-title":"Chest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1183\/09031936.00132804","article-title":"A Proposed Classification System of Central Airway Stenosis","volume":"30","author":"Freitag","year":"2007","journal-title":"Eur Respir J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198711000-00003","article-title":"Major and Massive Hemoptysis: Reassessment of Conservative Management","volume":"294","author":"Corey","year":"1987","journal-title":"Am J Med Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"358","DOI":"10.21037\/atm.2019.04.91","article-title":"Management of Hemoptysis in Patients with Lung Cancer","volume":"7","author":"Gershman","year":"2019","journal-title":"Ann Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1994.tb02936.x","article-title":"A Review of 79 Thymomas: Modification of Staging System and Reappraisal of Conventional Division Into Invasive and non-Invasive Thymoma","volume":"44","author":"Koga","year":"1994","journal-title":"Pathol Int"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2280","article-title":"Thymoma: State of the Art","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2003.10.001","article-title":"Thymic Tumors","volume":"77","author":"Detterbeck","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1038\/s41598-018-30417-6","article-title":"Inhibiting the CD8 + T Cell Infiltration in the Tumor Microenvironment After Radiotherapy is an Important Mechanism of Radioresistance","volume":"8","author":"Chen","year":"2018","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1177\/0300060519855595","article-title":"Radiotherapy Activates Autophagy to Increase CD8 + T Cell Infiltration by Modulating Major Histocompatibility Complex Class-I Expression in non-Small Cell Lung Cancer","volume":"47","author":"Zeng","year":"2019","journal-title":"J Int Med Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2020.11550","article-title":"Efficacy and Safety of CT-guided 125 I Brachytherapy in Elderly Patients with non-Small Cell Lung Cancer","volume":"20","author":"Zhao","year":"2020","journal-title":"Oncol Lett"},{"key":"B38","doi-asserted-by":"publisher","first-page":"14803","DOI":"10.1038\/s41598-019-51458-5","article-title":"Radiation-Related Adverse Effects of CT-guided Implantation of 125 I Seeds for Thoracic Recurrent and\/or Metastatic Malignancy","volume":"9","author":"Ji","year":"2019","journal-title":"Sci Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.09.070","article-title":"Stereotactic Body Radiation Therapy for Patients With Lung Cancer Previously Treated with Thoracic Radiation","volume":"78","author":"Kelly","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.01.012","article-title":"Stereotactic Body Radiation Therapy for Re-Irradiation of Persistent or Recurrent non-Small Cell Lung Cancer","volume":"88","author":"Trovo","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.640131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T06:52:30Z","timestamp":1622443950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.640131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":40,"alternative-id":["10.3389\/fonc.2021.640131"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.640131","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"article-number":"640131"}}